Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

Bayer AG. (7/21/17). "Press Release: Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma [Not intended for U.S. and UK Media]". Berlin.

Organisations Organisation Bayer AG
  Group Bayer (Group)
  Organisation 2 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
Products Product anetumab ravtansine (BAY 94-9343)
  Product 2 clinical research
Person Person LaCaze, Robert (Bayer 201702– EVP of new Oncology Strategic Business Unit joined 2015 from BMS)
     


   
Record changed: 2017-07-26

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px




» top